Therapeutic Drug Monitoring — MCQs
Variation in sensitivity of response to different doses of a drug in different individuals is obtained from?
A patient on digoxin therapy presents with atrial fibrillation and controlled ventricular rate. Upon evaluation, the patient's serum digoxin levels are elevated compared to previous values. Which of the following concomitant medications is most likely to have contributed to the enhanced digoxin toxicity?
What is the most appropriate statistical test to test the statistical significance of the change in blood cholesterol levels after a month's treatment with atorvastatin?
Which one of the following drugs has a narrow therapeutic range?
In which phase of clinical trials is drug dosing typically determined?
Match the following drugs in Column A with their contraindications in Column B. | Column A | Column B | | :-- | :-- | | 1. Morphine | 1. QT prolongation | | 2. Amiodarone | 2. Thromboembolism | | 3. Vigabatrin | 3. Pregnancy | | 4. Estrogen preparations | 4. Head injury |
Therapeutic index of a drug is an indicator of its:
After IV drug administration, elimination of a drug depends on:
Therapeutic drug monitoring is done for:
Which study design is most effective for investigating rare adverse effects of a drug?
Therapeutic Drug Monitoring Indian Medical PG Practice Questions and MCQs
Question 1: Variation in sensitivity of response to different doses of a drug in different individuals is obtained from?
- A. Dose-response relationship (Correct Answer)
- B. Therapeutic index
- C. Bioavailability
- D. Phase 1 clinical trials
Explanation: ***Dose-response relationship*** - The **dose-response relationship** (particularly the **graded dose-response curve**) describes how the magnitude of a drug's effect changes with different doses. - When plotted for different individuals or populations, these curves reveal **variation in sensitivity** through differences in potency (horizontal shift) and efficacy (maximum response). - This relationship helps characterize inter-individual variability in drug response and is the fundamental concept for understanding differential sensitivity. *Therapeutic index* - The **therapeutic index** is a measure of drug safety, representing the ratio between the toxic dose and the effective dose (TD50/ED50 or LD50/ED50). - It does not directly explain the variation in sensitivity to different doses among individuals, but rather provides information about the drug's overall safety margin. *Bioavailability* - **Bioavailability** refers to the fraction of an administered drug that reaches the systemic circulation unchanged. - While it influences the drug concentration at the site of action, it doesn't directly measure the variability in physiological response to that concentration among individuals. *Phase 1 clinical trials* - **Phase 1 clinical trials** are the first stage of testing a new drug in humans, primarily focusing on safety, dosage range, and pharmacokinetics in a small group of healthy volunteers. - While variability in response may be observed during these trials, they are not the *pharmacological concept* that describes this variation; rather, dose-response relationships are used to interpret findings from these trials.
Question 2: A patient on digoxin therapy presents with atrial fibrillation and controlled ventricular rate. Upon evaluation, the patient's serum digoxin levels are elevated compared to previous values. Which of the following concomitant medications is most likely to have contributed to the enhanced digoxin toxicity?
- A. Triamterene
- B. KCL
- C. Atenolol
- D. Clarithromycin (Correct Answer)
- E. Amiodarone
Explanation: ***Clarithromycin*** - **Clarithromycin** is a **macrolide antibiotic** known to inhibit the cytochrome P450 3A4 (CYP3A4) enzyme system and **P-glycoprotein**. - This inhibition leads to decreased metabolism and **efflux of digoxin**, resulting in **increased serum digoxin levels** and enhanced toxicity. - Among the options, clarithromycin is the **most common cause** of elevated digoxin levels through P-gp inhibition. *Triamterene* - **Triamterene** is a **potassium-sparing diuretic** that can increase serum potassium. - **Hyperkalemia** generally *reduces* the binding of digoxin to Na+/K+-ATPase, thereby potentially *reducing* its toxic effects. - Does not significantly affect digoxin serum levels. *KCL* - **Potassium chloride (KCl)** is used to correct **hypokalemia**. - **Hypokalemia** can *potentiate* digoxin toxicity because low potassium increases digoxin binding to the Na+/K+-ATPase pump. - However, KCl supplementation *corrects* hypokalemia and would actually *reduce* toxicity risk, not increase serum digoxin levels. *Atenolol* - **Atenolol** is a **beta-blocker** primarily used to control heart rate and blood pressure. - While it can slow the heart rate like digoxin (additive pharmacodynamic effect), it does not significantly alter the **pharmacokinetics** or serum levels of digoxin. *Amiodarone* - **Amiodarone** is an **antiarrhythmic** that can inhibit P-glycoprotein and increase digoxin levels. - However, in this scenario, **clarithromycin** is more commonly associated with acute elevations in digoxin levels in clinical practice. - Amiodarone interactions are well-known and typically require dose adjustments at initiation.
Question 3: What is the most appropriate statistical test to test the statistical significance of the change in blood cholesterol levels after a month's treatment with atorvastatin?
- A. Paired t-test (Correct Answer)
- B. Unpaired or independent t-test
- C. Analysis of variance
- D. Chi-square test
Explanation: ***Paired t-test*** * A **paired t-test** is appropriate when comparing two means from the **same group of subjects** measured at two different time points (before and after treatment). * In this scenario, a single group's blood cholesterol levels are measured *before* and *after* atorvastatin treatment, making the observations dependent. *Unpaired or independent t-test* * An **unpaired t-test** is used to compare the means of two *independent* groups. * It would be used, for instance, if cholesterol levels were being compared between a group receiving atorvastatin and a separate control group. *Analysis of variance* * **Analysis of variance (ANOVA)** is used to compare **three or more means**. * It would be appropriate if there were multiple treatment groups or multiple time points for comparison beyond just two. *Chi-square test* * The **Chi-square test** is used to examine the association between **categorical variables**. * It would not be suitable here, as blood cholesterol level is a continuous numerical variable, not a categorical one.
Question 4: Which one of the following drugs has a narrow therapeutic range?
- A. Propranolol
- B. Phenytoin (Correct Answer)
- C. Piroxicam
- D. Prazosin
Explanation: ***Phenytoin*** - **Phenytoin** has a **narrow therapeutic index**, meaning there is a small difference between the therapeutic and toxic doses. - This necessitates **therapeutic drug monitoring** to ensure effective treatment while avoiding adverse effects like nystagmus, ataxia, or gingival hyperplasia. *Propranolol* - **Propranolol** is a **beta-blocker** used for hypertension, angina, and arrhythmias, generally considered to have a wide therapeutic range. - While dose adjustments are common, routine therapeutic drug monitoring is typically **not required** due to its relatively safe profile at higher doses compared to drugs like phenytoin. *Piroxicam* - **Piroxicam** is a **nonsteroidal anti-inflammatory drug (NSAID)** with a relatively wide therapeutic window. - Its primary concerns are gastrointestinal and renal side effects rather than toxicity from a narrow therapeutic range. *Prazosin* - **Prazosin** is an **alpha-1 adrenergic blocker** used for hypertension and benign prostatic hyperplasia, and it generally has a wide therapeutic range. - The main concern with prazosin is **first-dose phenomenon** (orthostatic hypotension), which is an initial effect rather than toxicity from a narrow therapeutic window.
Question 5: In which phase of clinical trials is drug dosing typically determined?
- A. Phase 1 (Correct Answer)
- B. Phase 2
- C. Phase 3
- D. Phase 4
- E. Phase 0
Explanation: ***Phase 1*** - This phase involves a small group of **healthy volunteers** to assess the drug's safety, **pharmacokinetics (PK)**, and establish an initial dosing range. - The primary goal is to determine a **safe dosage level**, establish the **maximum tolerated dose (MTD)**, and identify potential side effects. - This is where drug dosing is **typically determined**. *Phase 0* - This is an exploratory phase involving **microdosing** studies with subtherapeutic doses. - The goal is to gather preliminary PK/PD data, but **not to determine therapeutic dosing**. *Phase 2* - This phase involves a larger group of **patients** with the condition to be treated. - The main goal is to evaluate the drug's **effectiveness** and further assess safety, but not primarily to determine initial dosing. *Phase 3* - This phase involves a large number of patients across multiple sites to confirm the drug's **efficacy** and monitor side effects in a broader population. - Dosing strategies have generally been established in earlier phases, and this phase primarily validates them. *Phase 4* - This phase occurs **after a drug has been approved** and marketed. - It involves ongoing surveillance to monitor long-term effects, collect additional information on safety, and identify new uses, but not initial dose determination.
Question 6: Match the following drugs in Column A with their contraindications in Column B. | Column A | Column B | | :-- | :-- | | 1. Morphine | 1. QT prolongation | | 2. Amiodarone | 2. Thromboembolism | | 3. Vigabatrin | 3. Pregnancy | | 4. Estrogen preparations | 4. Head injury |
- A. A-1, B-3, C-2, D-4
- B. A-4, B-1, C-3, D-2 (Correct Answer)
- C. A-3, B-2, C-4, D-1
- D. A-2, B-4, C-1, D-3
Explanation: ***A-4, B-1, C-3, D-2*** - **Morphine** is contraindicated in **head injury** as it can increase intracranial pressure and mask neurological symptoms. - **Amiodarone** is contraindicated in patients with **QT prolongation** due to its risk of inducing more severe arrhythmias like Torsades de Pointes. - **Vigabatrin** is contraindicated during **pregnancy** due to its potential for teratogenicity and adverse effects on fetal development. - **Estrogen preparations** are contraindicated in patients with a history of **thromboembolism** due to their increased risk of blood clot formation. *A-1, B-3, C-2, D-4* - This option incorrectly matches **Morphine** with QT prolongation and **Estrogen preparations** with head injury, which are not their primary contraindications. - It also incorrectly links **Vigabatrin** with thromboembolism and **Amiodarone** with pregnancy. *A-3, B-2, C-4, D-1* - This choice incorrectly associates **Morphine** with pregnancy and **Vigabatrin** with head injury, which are not the most critical or direct contraindications. - It also misaligns **Amiodarone** with thromboembolism and **Estrogen preparations** with QT prolongation. *A-2, B-4, C-1, D-3* - This option incorrectly matches **Morphine** with thromboembolism and **Amiodarone** with head injury, which are not their most significant contraindications. - It also incorrectly links **Vigabatrin** with QT prolongation and **Estrogen preparations** with pregnancy.
Question 7: Therapeutic index of a drug is an indicator of its:
- A. Effectiveness
- B. Adverse Effects
- C. Therapeutic Effect
- D. Safety Profile (Correct Answer)
Explanation: ***Safety Profile*** - The **therapeutic index (TI)** is a ratio that compares the dose of a drug that produces a **toxic effect** to the dose that produces a **therapeutically desired effect**. - A higher therapeutic index generally indicates a **safer drug**, as it means a larger dose is required to cause toxic effects compared to the therapeutic dose. *Effectiveness* - While related to efficacy, effectiveness usually refers to how well a drug works in **real-world clinical practice**, not directly measured by the therapeutic index. - The therapeutic index focuses on the **margin between efficacy and toxicity**, rather than just the degree of positive response. *Adverse Effects* - The **therapeutic index** considers the toxic dose, which leads to adverse effects, but it's a measure of the **margin of safety**, not just the presence or absence of adverse effects. - It quantifies the **risk of adverse effects** relative to the therapeutic benefit, rather than simply listing or describing them. *Therapeutic Effect* - The **therapeutic index** incorporates the dose required for a therapeutic effect, but its primary purpose is to assess the **risk of toxicity** in relation to that therapeutic effect. - It's a measure of the **balance between benefit and harm**, not solely the therapeutic benefit itself.
Question 8: After IV drug administration, elimination of a drug depends on:
- A. Lipid solubility
- B. Volume of distribution
- C. Clearance (Correct Answer)
- D. All of the options
Explanation: ***Clearance*** - **Clearance (CL)** is the primary and direct determinant of drug elimination after IV administration. - It represents the **volume of plasma cleared of drug per unit time** (e.g., mL/min or L/hr). - The **rate of elimination** is directly calculated as: Rate = CL × Plasma concentration - Clearance integrates the efficiency of all eliminating organs (liver, kidneys) and is the key parameter determining how fast a drug is removed from the body. - Formula: **CL = Rate of elimination / Plasma concentration** *Lipid solubility* - Lipid solubility affects drug **distribution** and **renal reabsorption** but does not directly determine the rate of elimination. - Highly lipid-soluble drugs may be reabsorbed in renal tubules, but the elimination rate is still governed by clearance. - Lipid solubility is more relevant to drug distribution and metabolism pathways than to the rate of elimination itself. *Volume of distribution* - Volume of distribution (Vd) describes how extensively a drug distributes into tissues versus plasma. - While Vd affects the **half-life** (t½ = 0.693 × Vd/CL), it does NOT directly determine the elimination rate. - A large Vd means more drug in tissues, which affects how long elimination takes, but the actual rate of elimination is still determined by clearance. - Vd is a distribution parameter, not an elimination parameter. *All of the options* - This is incorrect because only **clearance** directly determines the rate of drug elimination. - While lipid solubility and volume of distribution can indirectly influence how long a drug remains in the body, they do not determine the elimination rate itself—clearance does.
Question 9: Therapeutic drug monitoring is done for:
- A. Aspirin
- B. Heparin
- C. Phenytoin (Correct Answer)
- D. Metformin
Explanation: ***Phenytoin*** - **Phenytoin** has a **narrow therapeutic window**, meaning the difference between an effective and a toxic dose is small, necessitating close monitoring. - Its **variable absorption** and **nonlinear pharmacokinetics** (saturable metabolism) make individual dosing adjustments critical to maintain therapeutic levels and avoid toxicity. *Aspirin* - **Aspirin** is generally not monitored via plasma levels for its analgesic or antiplatelet effects, as its therapeutic effects are often observed at doses where plasma monitoring is not practical or necessary. - Its primary therapeutic use as an **antiplatelet agent** is evaluated by clinical outcomes rather than drug concentration. *Heparin* - **Heparin** is monitored using coagulation tests like **aPTT (activated partial thromboplastin time)** or anti-Xa levels to assess its anticoagulant effect, not direct drug concentration. - Therapeutic drug monitoring for heparin focuses on its **pharmacodynamic effects** on the clotting cascade rather than its absolute plasma concentration. *Metformin* - **Metformin** has a relatively **wide therapeutic index** and its efficacy is primarily measured by reductions in blood glucose and HbA1c, not by plasma drug concentrations. - It is excreted largely unchanged by the kidneys, and dose adjustments are typically made based on **renal function** and glycemic control.
Question 10: Which study design is most effective for investigating rare adverse effects of a drug?
- A. Cohort study
- B. Cross-sectional study
- C. Case-control study (Correct Answer)
- D. Clinical trial/experimental study
Explanation: ***Case-control study*** - This design starts by identifying individuals with the **rare adverse effect (cases)** and a control group without the effect to look back for exposure to the drug. - It is efficient for studying rare outcomes because it doesn't require following a large population for a long time to observe few events. *Cohort study* - A **cohort study** follows a group of individuals exposed and unexposed to a drug forward in time to observe outcomes. - While good for common outcomes, it would require an **extremely large sample size** and a long follow-up period to observe rare adverse drug effects. *Cross-sectional study* - A **cross-sectional study** assesses exposure and outcome simultaneously at a single point in time. - This design is suitable for determining **prevalence** but cannot establish temporal relationships between drug exposure and rare adverse effects, nor is it efficient for rare outcomes. *Clinical trial/experimental study* - **Clinical trials** are primarily designed to test the efficacy and safety of new interventions, usually focusing on common adverse effects. - They are generally **not powered** or long enough to detect rare adverse events, as such events would occur in very few participants, if any.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free